Blank

Lopinavir pharmacokinetics

Common Questions and Answers about Lopinavir pharmacokinetics

kaletra

Avatar m tn Hi everyone, I have take a PEP treatment for 25 days, which included Lopinavir&Ritrnonavir & Truvada. I have had diarrhea, anxiety, sleepless nights, depression, numbness in hands and legs, while using these medications. Its been a week i stopped the medication and all my HIV tests have been negative so far.
Avatar m tn Has anyone read the news that came out yesterday about hpv treatment with the Lopinavir drug? It shows some promising results so I'd like to get anyone's take on this.
Avatar n tn - Absorption, oral: time to peak concentration 7h - Elimination half-life = 12 h (It says also that in general it can be administered once daily because it has a 24 h effect.Why?) - Can you give another example to clarify it better please? - When it says divide in 2 doses , does it mean only in the morning and dinner? 3 doses (morning-lunch-dinner)? Thank you for taking the time to answer!!
4865450 tn?1361294533 have them laser removed and immediately start using an aldara and celebrex combo for a year. tell your doc you are really stiff or something to get the celebrex... maybe do some research and tell your doc what he/she needs to hear because insurance isn't going to cover it for your warts but it has been proven to work. it's not FDA approved yet.. too new of a treatment. There is an HIV drug that cures HPV as well, it's called Lopinavir - also not FDA approved for HPV.
Avatar f tn This study has to do with an HIV retroviral medication, if used on HPV patients, it might cure them. The drug is already produced, called lopinavir, however we need to make a topical version that is more potent: http://bodywart.com/hpv-news/lopinavir-destroy-hpv-infected-cells/ You might also want to look into a antiviral drug recently produced by MIT called DRACO. It sounds very promising but needs to be tested on actual humans.
Avatar m tn 1 - would PEP be effective even if the source has a high viral load? 2 - After the 28 days, can I drink alcohol? Thank you very much in advance, I am quite distressed about it.
446474 tn?1446347682 * Boceprevir reduced average trough concentrations of ritonavir-boosted atazanavir (Reyataz), lopinavir (Kaletra), and darunavir (Prezista) by 49%, 43% and 59%, respectively. * On average, reductions of 25% to 36% were seen in peak concentration of the three drugs, when given with boceprevir, along with declines of 34% to 44% in exposure (area under the curve).
Avatar m tn Zidovudine and Lamivudine Tablets ,Lopinavir/RitonavirOral Solution .i want to know ,will it work?how much percent will i avoid being infected?thank you all!
Avatar f tn So, I am at the 15th day of my pep regime and have been strictly adhering to the program till today. I have been taking lopinavir ritonavir along with tenofovir. I am taking 2pills twice for the first one and one pill once a day for tenofovir. Today my bottle of rito/lopi finished after I took my first dose. I went to the doc clinic which was closed and he says i can only get the meds tomorrow.
Avatar n tn 11,12am), I take hiv block drugs from doctor, these drugs are Tenofovir Disoproxil Fumarate Tablets , Aluvia (Lopinavir and Ritonavir Tablets) and Lamivudine Tablets. I have take these drugs for 28 days (until 2013.10.8),at 2013.10.9(1 day after taking drugs) , I have take a HIV Duo or Combo (4th generation) test and the result is negative . so, I want to know 1. Could these drugs delay the hiv window period , so that the combo tese was not correct? 2.
Avatar m tn 1-My partner tested Negative(Antigen/ Antibody) on 22 days post exposure 2-Thinking that i might be developing facial Lipodystrophy (slight facial fat loss under cheek bones). I cant tell if my face was like this before the treatment or it is just an illusion. What can i do to really know if i developed some lipodystrophy ? any test u can advise about?
Avatar m tn This is known. Are there any similar action in the protease inhibitor, such as Kaletra (lopinavir) for example? Have you ever thought about that? I read - sometimes laugh. Simvastatin, vitamin D, which the Chinese poeben, mythical new drugs, masturbation with measurements of the level of HBsAg, and other nonsense....
863555 tn?1239133228 Yes, it sounds interesting, indeed. I recognized retonavir, since I'm using it in my HIV cocktail, too. In my case to boost lopinavir. (The other two I use are emtricitabine and tenofovir). Daily, I use 200 mg of retonavir to boost 800 mg of lopinavir. I read in the study that 100 or 200 mg of retonavir is used to boost 200, 400 or 600 mg of SCH 900518/boceprevir. My HIV is successfully suppressed (i.e. UND) after two weeks of interferon -- that's three weeks ago.
Avatar m tn What is my overall risk of acquiring HIV, taking in consideration all that I have described above?. Thank you very much in advance.
Avatar m tn I can't help out on the pharmacokinetics, but your reasoning is sound: it doesn't make sense to dose so that the drug runs out. I'd query Schering-Plough as well as your hepatologist, if I were you. Please give me a heads-up if you solve the riddle.
7510956 tn?1411671417 //www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm375286.
Avatar m tn Hepatic Impairment In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for Cmax and 85% for AUC). The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not been studied. A starting dose of 25 mg should be considered in patients with any degree of hepatic impairment [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].
Avatar f tn Folic acid supplementation in folate-deficient patients with epilepsy changes the pharmacokinetics of phenytoin, usually leading to lower serum phenytoin concentrations and possible seizure breakthrough..." It however says that initiation of Folic acid and phenytoin together is beneficial. Since you can't go back and start all over again, you can take a small dose. It has been observed that as los as 1mg dose can perturb phenytoin’s levels, You may take doses lower than 1mg/day.
863754 tn?1239144755 However, physiological changes resulting from smoking cessation may alter the pharmacokinetics or pharmacodynamics of insulin; dosage adjustments may be necessary.
Avatar n tn A 12 years old girl had a blood transfusion with hiv blood, she took PEP( tenofovir, emtricitabine, ritonavir-boosted darunavir (subsequently changed to lopinavir) and raltegravir) after 24 hours and had these PEP for three months. This girl also has cssr5 dna which is a dna that hard to infect hiv. After 8 months, she had a negative result on HIV RNA and HIV ag/ab test. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226216/).
Avatar m tn The Phase 1 trial was designed to characterize the safety profile of ARC-520 across a range of doses and evaluate pharmacokinetics. It is a single-center, randomized, double-blind, placebo-controlled, single dose-escalation, first-in-human study of ARC-520 administered intravenously to healthy adult volunteers. All subjects have been dosed and received either placebo or ARC-520 in doses ranging from 0.01 mg/kg to 2 mg/kg.
Avatar f tn i believe in the pre-clinical trials with healthy volunteers, researchers used Carbon14 to gauge the half-life and paths of elimination during pharmacokinetics studies. it is a common practice. perhaps that is what you are thinking about?
29837 tn?1414534648 The pharmacokinetics of ledipasvir were studied with a single dose of 90 mg ledipasvir in HCV negative subjects with severe hepatic impairment (Child-Pugh Class C). Ledipasvir plasma exposure (AUC0-inf) was similar in subjects with severe hepatic impairment and control subjects with normal hepatic function. Population pharmacokinetics analysis in HCV-infected subjects indicated that cirrhosis had no clinically relevant effect on the exposure of ledipasvir [see Use in Specific Populations (8.
808353 tn?1238293321 The combination of two potent direct-acting antivirals (DAAs), targeting two distinct viral enzymes, may offer advantages over single DAA strategies by enhancing potency, reducing the emergence of drug resistance, and possibly eliminating the need for PEG-IFN +/- ribavirin. The combination of R7128/R7227 offers the potential for a highly potent regimen with a high genetic barrier to resistance. Methods: INFORM-1 is a randomized, double-blind, ascending dose Phase I trial.